Metal nanoenzymes have made important progress in the treatment of Parkinson's disease

recently, Xu Chang College and the Johns Hopkins University School of Medicine in the United States, Tsinghua University Department of Chemistry team, in the nanoenzyme for the treatment of neurological diseases made new progress. The findings were published in Nano Today, an academic journal in the field of nanoscience.
the world's second-largest neurodegenerative disease, Parkinson's disease (PD) is about 1.7% prevalent among people over 65 years of age in China. Parkinson's disease is characterized by abnormal accumulation and accumulation of α-synactal nucleoproteins in the body, and there is no effective treatment and prevention method.
In recent years, international scholars have suggested that pathological α-synaptic nucleoproteins are virus-like proteins that can spread from one region to another in the PD brain, increasing the pathological evolution of PD. Many new studies have shown that elevated oxidative stress levels are a α cause the spread of virus-like nuclear proteins. Therefore, finding nanomaterials that can effectively reduce oxidative stress levels and are biocompa compatible may inhibit the spread of pathological α-synaptic nucleoproteins, which can play an important role in reducing the incidence of PD.
In response to this challenging problem, Xuchang College Professor He Weiwei, Zheng Zhi team combined with the previous years of research accumulation in the precious metal nanoenzyme, with the United States Johns Hopkins University School of Medicine Professor Mao Xiaobo, Tsinghua University Department of Chemistry Professor Li Yanmei, designed a good biological compatibility of PtCu alloy nanoenzyme. Antioxidant experiments have shown that the nanoenzyme has multiple analog enzyme activity and the ability to remove free fundamentals, making PtCu nanoparticles an excellent antioxidant to inhibit the production of reactive oxygen species.
to evaluate the biological activity of PtCu nanoparticles in vitro and in vivo, the researchers built a α-synactical nucleoprotein prefabrised fibrous body (PFF)-induced model of Parkinson's disease. In-body cell experiments have shown that PtCu nanoenzyme can significantly reduce the level of reactive oxygen (ROS) induced by PFF, α-synaptic nucleoprotein pathology and neurotoxicity, and, importantly, the nanoenzyme can also block the spread of pathological α-synaptic nuclear protein cells. In experiments, PtCu nanoenzyme treatment significantly prevented the α-synactical nucleoproteins from spreading from the synth to the black matter. This is the first time that nanoenzymes have been found and proven to block the spread of α-synaptic nucleoproteins, providing a new strategy for the application of nanoenzymes in the treatment of PD diseases. (Source: Chen Bin, China Science Journal)
relevant paper information: